Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of September 2026. The report serves as a notification of transactions by a Person Discharging Managerial Responsibilities (PDMR) in accordance with the UK Market Abuse Regulation. Haleon operates as a consumer health company with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes and Transaction Details
The filing discloses a specific transaction involving the Senior Independent Non-Executive Director, Alan Stewart:
- Transaction Type: Acquisition of Ordinary Shares via dividend reinvestment.
- Date of Transaction: September 17, 2026.
- Volume: 242 shares.
- Price: £3.378619 per share.
- Exchange: London Stock Exchange (XLON).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard regulatory disclosure of the PDMR transaction.
Investor Verification Checklist
- Verify the total shareholding of Alan Stewart post-transaction to assess concentration levels.
- Confirm the dividend reinvestment plan terms applicable to directors.
- Review the broader market context for Haleon shares on September 17, 2026, to contextualize the transaction price.